There is an opportunity in Austria: the country is teeming with advanced research and strong talent, but much of it remains commercially untapped. 

Rumors have resurfaced that Novartis is looking to shift some of its eye drugs but the Basle-based behemoth tells Scrip it remains committed to in-market products and R&D projects in the ophthalmology space.

Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.

ON the lookout for potential ophthalmology options despite recent setbacks in the area, Novartis has now spotted ECF843, an investigative recombinant human lubricin – or natural lubricant – for dry eye.